{"schema_version":"secwatch.filing_event.v1","accession":"0001393905-23-000314","form_type":"8-K","ticker":null,"cik":"0001575659","company_name":"Rapid Therapeutic Science Laboratories, Inc.","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.397449+00:00","generated_at":"2026-06-11T04:48:07.989105+00:00","sec_items":["1.01","2.03","3.02","3.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RTSL extends $2.35M convertible debt to Dec 2023, issues 5M warrants at $0.01","bullets":["Amended two convertible debentures totaling $2,352,940; maturity extended to earliest of qualified offering, exchange listing, or Dec 31, 2023.","Conversion price set at 65% of lowest 10-day VWAP; existing warrants repriced to $0.01/share, extended to Aug 2028.","Issued new warrants for 5,000,000 shares at $0.01 with 5.5-year term expiring Feb 2029; full mutual release of all past claims.","Company had been in continuous default since Sep 2022; all prior defaults waived under the agreement.","Potential dilution includes 582,354 shares from existing warrants plus 5M from new warrants, all at $0.01."],"urls":{"canonical":"https://secwatch.observer/filing/0001393905-23-000314","json":"https://secwatch.observer/filing/0001393905-23-000314.json","markdown":"https://secwatch.observer/filing/0001393905-23-000314.md","text":"https://secwatch.observer/filing/0001393905-23-000314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/0001393905-23-000314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/rtsl-20230822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:48:07.989105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8677ffc8cd5945b70f4ff4cabd318a7c456dfafa","claim":"Rapid Therapeutic Science Laboratories, Inc. amended convertible notes of $1,941,176 with an accredited investor maturing no later than December 31, 2023.","evidence_excerpt":"(the “ Company ”, “ we ” or “ us ”), entered into a Second Amendment, Waiver and Purchase Agreement (the “Agreement”) with an accredited investor (the “ Purchaser ”), pursuant to which the Company amended the terms and extended the maturity of the following obligations: (i) Convertible Debenture payable to the Purchaser, dated August 1, 2021, in the total amount of $1,941,176; and (ii) Convertible Debenture payable to the Purchaser, dated May 31, 2022, in the total amount of $411,764, both of which are past due the current maturity date, until no later than December 31, 2023 (collectively, the “ Debentures ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/0001393905-23-000314-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$1,941,176"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Maturity","value":"no later than December 31, 2023"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"fb65e28ada9eafb15aff8f2f46f40cf68005fc92","claim":"Rapid Therapeutic Science Laboratories, Inc. amended convertible notes of $411,764 with an accredited investor maturing no later than December 31, 2023.","evidence_excerpt":"(the “ Company ”, “ we ” or “ us ”), entered into a Second Amendment, Waiver and Purchase Agreement (the “Agreement”) with an accredited investor (the “ Purchaser ”), pursuant to which the Company amended the terms and extended the maturity of the following obligations: (i) Convertible Debenture payable to the Purchaser, dated August 1, 2021, in the total amount of $1,941,176; and (ii) Convertible Debenture payable to the Purchaser, dated May 31, 2022, in the total amount of $411,764, both of which are past due the current maturity date, until no later than December 31, 2023 (collectively, the “ Debentures ”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/0001393905-23-000314-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$411,764"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Maturity","value":"no later than December 31, 2023"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"75448f376d874011da15c20687119a50718e09d3","claim":"Rapid Therapeutic Science Laboratories, Inc. amended Second Amendment, Waiver and Purchase Agreement with an accredited investor valued at $2,352,940 (effective 2023-08-22).","evidence_excerpt":"On August 22, 2023, Rapid Therapeutic Science Laboratories, Inc. (the “ Company ”, “ we ” or “ us ”), entered into a Second Amendment, Waiver and Purchase Agreement (the “Agreement”) with an accredited investor (the “ Purchaser ”), pursuant to which the Company amended the terms and extended the maturity of the following obligations: (i) Convertible Debenture payable to the Purchaser, dated August 1, 2021, in the total amount of $1,941,176; and (ii) Convertible Debenture payable to the Purchaser, dated May 31, 2022, in the total amount of $411,764, both of which are past due the current maturity date, until no later than December 31, 2023 (collectively, the “ Debentures ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1575659/000139390523000314/0001393905-23-000314-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"$2,352,940"},{"label":"Effective","value":"2023-08-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}